Laminin-111 improves muscle repair in a mouse model of merosin-deficient congenital muscular dystrophy
Authors:
Open Access
- 5 September 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 23 (2) , 383-396
Abstract
Merosin-deficient congenital muscular dystrophy type 1A (MDC1A) is a severe and fatal muscle-wasting disease with no cure. MDC1A patients and the dyW−/− mouse model exhibit severe muscle weakness, demyelinating neuropathy, failed muscle regeneration and premature death. We have recently shown that laminin-111, a form of laminin found in embryonic skeletal muscle, can substitute for the loss of laminin-211/221 and prevent muscle disease progression in the dyW−/− mouse model. What is unclear from these studies is whether laminin-111 can restore failed regeneration to laminin-α2-deficient muscle. To investigate the potential of laminin-111 protein therapy to improve muscle regeneration, laminin-111 or phosphate-buffered saline-treated laminin-α2-deficient muscle was damaged with cardiotoxin and muscle regeneration quantified. Our results show laminin-111 treatment promoted an increase in myofiber size and number, and an increased expression of α7β1 integrin, Pax7, myogenin and embryonic myosin heavy chain, indicating a restoration of the muscle regenerative program. Together, our results show laminin-111 restores muscle regeneration to laminin-α2-deficient muscle and further supports laminin-111 protein as a therapy for the treatment of MDC1A.Keywords
This publication has 48 references indexed in Scilit:
- A call for transparent reporting to optimize the predictive value of preclinical researchNature, 2012
- Deletion of periostin reduces muscular dystrophy and fibrosis in mice by modulating the transforming growth factor-β pathwayProceedings of the National Academy of Sciences, 2012
- Laminin-111 Protein Therapy Reduces Muscle Pathology and Improves Viability of a Mouse Model of Merosin-Deficient Congenital Muscular DystrophyThe American Journal of Pathology, 2012
- Assessment of proteolytic degradation of the basement membrane: a fragment of type IV collagen as a biochemical marker for liver fibrosisFibrogenesis & Tissue Repair, 2011
- Apoptosis inhibitors and mini‐agrin have additive benefits in congenital muscular dystrophy miceEMBO Molecular Medicine, 2011
- Muscle-specific expression of insulin-like growth factor 1 improves outcome in Lama2Dy-w mice, a model for congenital muscular dystrophy type 1AHuman Molecular Genetics, 2011
- Skeletal muscle laminin and MDC1A: pathogenesis and treatment strategiesSkeletal Muscle, 2011
- The C-terminal Region of Laminin β Chains Modulates the Integrin Binding Affinities of LamininsJournal of Biological Chemistry, 2009
- Pathology is alleviated by doxycycline in a laminin‐α2–null model of congenital muscular dystrophyAnnals of Neurology, 2009
- Linker molecules between laminins and dystroglycan ameliorate laminin-α2–deficient muscular dystrophy at all disease stagesJournal of Cell Biology, 2007